CN Patent

CN111163795A — 用于治疗肥胖症的mic-1和glp-1

Assigned to Novo Nordisk AS · Expires 2020-05-15 · 6y expired

What this patent protects

本发明涉及用于预防和/或治疗肥胖症的MIC‑1化合物，其中所述MIC‑1化合物与GLP‑1化合物同时、分开或依次施用。

USPTO Abstract

本发明涉及用于预防和/或治疗肥胖症的MIC‑1化合物，其中所述MIC‑1化合物与GLP‑1化合物同时、分开或依次施用。

Drugs covered by this patent

Patent Metadata

Patent number
CN111163795A
Jurisdiction
CN
Classification
—
Expires
2020-05-15
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.